Inflammation is a well-coordinated process in response to tissue injury or infection aimed at restoration of tissue homoeostasis. Platelets and neutrophils are typically viewed important in the context of haemostasis and bacterial killing, respectively. However, as these cells are equipped with readily available armoury, both have received much attention for their importance in shaping the early inflammatory reaction in recent years. While some of these activities are executed individually, both cells join forces during much of their pro-inflammatory activities. This brief review summarizes recently identified mechanisms of neutrophilplatelet interaction and describes functional consequences on neutrophil trafficking and the release of neutrophil extracellular traps. Moreover, the synergy of neutrophils and platelets during the recruitment of monocytes is reviewed. Finally, this review discusses how knowledge on the intimate neutrophil-platelet partnership can be employed to design interventional strategies.
| INTRODUCTION
Inflammation is a tightly regulated process initiated by tissue injury or infection. To eliminate the pathogenic insult or to remove damaged tissue, a coordinated cascade of events is rapidly unleashed aimed at restoring tissue homoeostasis. 1 Among circulating leucocytes, neutrophils are the first ones to respond to tissue injury. Their ability to act in large numbers with the help of a preformed machinery allows for containment of the inflammatory trigger. 2, 3 Although being key players in haemostasis, platelets have in recent years been recognized for their crucial importance during early inflammatory responses. [4] [5] [6] Platelets possess a broad arsenal of adhesion molecules and receptors allowing for promiscuous physical interaction with neutrophils. Such interaction may facilitate and accelerate neutrophil recruitment as well as change the fate of neutrophils. With regard to the latter, the encounter of platelets by neutrophils impacts on their life span, possibly increasing or inhibiting neutrophil apoptosis and facilitating the release of neutrophil extracellular traps (NETs). In this brief review, I will summarize recent findings on mechanisms of the interaction of neutrophils and platelets and highlight consequences of this interaction with regard to neutrophil functionality. In addition, I review the cooperativity of neutrophils and platelets during recruitment of monocytes. Finally, I will provide recent approaches how interventional strategies can be employed to boycott the before-discussed inflammatory loops.
inflammatory bowel disease (IBD). [7] [8] [9] Following the onset of inflammation, neutrophils and platelets in the circulation are rapidly activated by initiating several well-coordinated processes controlling luminal as well as abluminal inflammation. Upon activation, platelet integrins change their conformation from a low-affinity to high-affinity state allowing specific interaction with respective ligands. aIIbb3 integrin is the most abundant adhesion molecule on platelets. When activated, it binds fibrinogen which in turn allows the binding of aMb2 integrin on neutrophils thereby allowing for neutrophil-platelet complex formation.
10,11
The same neutrophil integrin also bridges with platelet GPIb. This cellular interaction is complemented by the interaction of neutrophil aLb2 integrin with ICAM2 on platelets. Beyond integrins, heterotypic neutrophil-platelet interactions are also supported by selectins. Upon platelet activation, P-selectin is incorporated into the plasma membrane, which may subsequently bind to P-selectin glycoprotein ligand 1 (PSGL1) on myeloid cells. 12 Recently, it has been shown that PSGL1 is displayed on luminal protrusions of polarized neutrophils that adhere to the endothelium. Its ligation by P-selectin on activated platelets licenses neutrophils to migrate towards endothelial junctions. 13 Beyond direct interaction, platelets activate neutrophils by soluble mediators with CXC chemokines such as CXCL2, CXCL4, CXCL5, CXCL7 and CXCL8 being of primary importance.
14 These ligate-specific G-protein coupled receptors on neutrophils and predominantly control neutrophil trafficking. In addition, other neutrophil functions including NET release and apoptosis are controlled by platelet chemokines. 15, 16 However, chemokines often function in homo or heterocomplexes which can enhance or mitigate chemokine function. A classic example of enhanced function of chemokine heteromers is the CCL5-CXCL4 heteromer. Both chemokines released from activated platelets promote myeloid cell activation and adhesion to a larger degree as a heteromer as compared to acting alone. 17, 18 Upon activation, platelets also secrete damage-associated molecular patterns, including HMGB1. Externalized HMGB1 is recognized by RAGE on neutrophil resulting in neutrophil activation. 19, 20 Of note, HMGB1 can also for a heterocomplex with CXCL12 and hereby engage CXCR4 to enhance neutrophil recruitment to sites of inflammation. 21 
| ALTERATION OF NEUTROPHIL FUNCTION BY PLATELETS
Due to the blood viscous properties during flow, platelets are pushed towards the vessel wall, while red blood cells remain in the centre of the vessel. In this constellation, leucocytes in proximity to the vessel wall are more likely to encounter platelets, enhancing the possibility of collisions between platelets and neutrophils. 22 Platelets adhere to the endothelium and in this location mediate neutrophil rolling via GPIb and GPIIb/IIIa. 23, 24 The main interaction between platelets and neutrophils, however, appears to be mediated by the binding of platelet P-selectin to PSGL1 on neutrophils. In fact, the engagement of neutrophil PSGL1 licenses neutrophil activation and subsequent transmigration. 13 Neutrophil recruitment has been shown to be increased by the formation of platelet-neutrophil aggregates. 25 In a variety of models, this interaction has been proven to be an essential prerequisite for neutrophil recruitment. 6 However, the physiological role of this interaction does not appear to be solely limited to mechanical functions of secondary neutrophil capture. Beyond the direct interaction of platelets with neutrophils, platelets may also be involved in maintaining the integrity of the vascular endothelium and thus indirectly modulate neutrophil recruitment. 26 Furthermore, the interaction of platelets with neutrophils has been demonstrated to enhance cell-autonomous functions in neutrophils involved in the defence and containment of invading exogenous pathogens. 15 The importance of platelets during the release of neutrophil extracellular traps (NETs) was initially identified in a mouse model of LPS-induced sepsis. 27 Ligation of TLR4 triggered neutrophil-platelet interaction in this model and subsequent release of NETs. However, platelet-mediated NET formation is not restricted to models of bacterial infection but was more recently also extended to viral infections. 28 Although the central role of platelets in NETosis was initially identified in infectious processes, it also occurs during sterile inflammation. In fact, activation of platelets, not only by pathogens but also by classical platelet agonists such as thrombin, arachidonic acid, collagen or ADP, results in NET induction. 20, [29] [30] [31] Such mechanisms may be important during acute lung injury but also atherosclerosis where the importance of both neutrophils and platelets has consistently been reported. 7, 9, 17, 25, [32] [33] [34] With the importance of platelets during the release of NETs, it seems crucial to understand the underlying mechanisms. The relevance of platelet TLR4 has been corroborated in both mice and humans. 27, 30 However, it is not yet clear whether the LPS bound to platelets interacts with neutrophil TLR4 or if the LPS triggers platelet activation which in turn sets off NET release. Another signalling pathway of relevance during this intimate interplay is the interaction of neutrophil CD18 and platelet GPIb. Mouse studies on CD18-deficient neutrophils demonstrated its importance in platelet-triggered NET release. Furthermore, blockade of Mac1 but not LFA1 reduced NET formation, an observation made for human and murine neutrophils alike. 15, 28 Similar observations were made for genetic deletion of inhibition of GPIb. 30 Beyond cell-cell interaction, soluble, platelet-derived mediators can also initiate NET release. Upon activation, platelets secrete HMGB1 which induces NET release by activation of neutrophil receptor for advanced glycation endproducts (RAGE). 20 Platelet alpha granules are rich in chemokines some of which not only just induce cell migration but also NET release. In this context, the aforementioned heteromer of PF4 and CCL5 promotes not only just recruitment of neutrophils to the injured lung 17 but also the release of NETs in the lung microvasculature, a finding also corroborated with human neutrophils. 15 Yet another platelet-borne signal-inducing NET release is b-defensin, an antimicrobial polypeptide enriched in epithelial cells and found in platelets in just smaller amounts. 35 By inducing NET release, b-defensin is able to boost its antimicrobial activity.
| PLATELET-NEUTROPHIL COOPERATIVITY DURING MONOCYTE RECRUITMENT
While acute inflammatory responses are dominated by neutrophilic leucocyte influx, monocytes and macrophages are generally the most prominent myeloid cells at sites of prolonged inflammation. Observations from patients and animal models indicate that neutrophils contribute to the accumulation of monocytic cells at inflammatory sites. 36 While several mechanisms of neutrophil-driven monocyte recruitment including chemokine maturation by neutrophil proteases and IL-6 trans-signalling have been identified as important contributors to neutrophil-guided monocyte recruitment, 37 the release of neutrophil-derived chemotactic molecules may be of primary importance. One such molecule is cathelicidin (human: LL37; mouse: CRAMP) which is stored in neutrophils in its preform hCAP18 and processed upon discharge from secondary granules by proteinase 3. 38 Due to its cationic nature, cathelicidin interacts with negatively charged endothelial cell surfaces and is in this way presented to circulating leucocytes. [39] [40] [41] Cathelicidin released from emigrated neutrophils is transported across the endothelium in a basoapical direction thus ensuring its accumulation on the endothelium. In this location, cathelicidin binds FPR2, a receptor expressed on myeloid cells and facilitates adhesion of monocytic cells, a process of importance during atherosclerosis and its complications. Also platelets have the ability to facilitate monocyte adhesion at sites of inflammation. Platelets directly interact with monocytes, leading to enhanced expression of CD40, PSGL1, CD11b and CCR2 on the monocyte surface. 42, 43 This, in turn, enhances platelet-monocyte aggregate formation and adhesion of monocytes to the endothelium. 44 , 45 In addition to direct platelet-monocyte interaction, plateletderived chemokines influence endothelial adhesion of monocytes. In this context, platelet-borne CXCL4, CCL5 and MIF promote monocyte arrest on activated endothelium. 46, 47 In recent years, mechanisms have been described by which neutrophils and platelets cooperate during the inflammatory monocyte recruitment. First, in a sequential cooperativity, platelets activated by high-shear forces secrete CCL5 which is deposited on arterial endothelial cells. Interestingly, the deposition of CCL5 predominantly at sites of high-shear forces initiates a recruitment mechanism restricted to large arteries. 48 CCL5 promotes the release of cathepsin G from neutrophils which in turn is laid onto arterial endothelial cells. For a reason not yet defined, cathepsin G was found to only bind to isolated arterial endothelial cells but not to endothelial cells of venous origin. Immobilized cathepsin G evokes an active response in rolling monocytes that induces shear-resistant adhesion strengthening in a process involving integrin clustering but independent of integrin conformation changes. Ultimately, this cascade of events promotes arterial-specific monocyte adhesion. 48 In a second mechanism involving a simultaneous cooperativity, neutrophil and platelet secretory products form protein heteromers to stimulate monocyte adhesion. Secretagogues released upon initiation of inflammation such as LTB4 or formylated peptides induce the discharge of preformed chemotactic molecules from neutrophils and platelets. The combination of the crude neutrophil and platelet secretion enhances monocyte adhesion in a CCR5-dependent manner. 49 In subsequent experiments, it was found that platelet-borne CCL5 forms heteromers with neutrophil-derived a-defensins (also known as human neutrophil peptides, HNPs) and hereby allows a-defensin to access CCR5. Downstream signalling induces a vigorous integrin activation and subsequent adhesion of human classical monocytes in vitro and of murine classical monocytes in the cremaster muscle as well as the infarcted heart. chemokines during leucocyte recruitment and prominent off-target effects owing to cross-reactivity with receptors of similar structure. Furthermore, targeted molecules are often important for other immune responses, and their blockade can compromise host defence. Recent studies have suggested ways to overcome such developmental hurdles. First, the elucidation of a sequential interaction of platelets and neutrophils in the context of monocyte recruitment with specificity to arterial vessels allows for the specific blockade of myeloid cell trafficking to certain vascular beds. In this context, a recent study has identified the importance of cathepsin G during arterial myeloid cell recruitment, a mechanism of minor relevance during microvascular myeloid cell adhesion. Accordingly, neutralization of cathepsin G in mouse models did not affect neutrophil extravasation during acute lung inflammation but instead specifically limited atherogenic leucocyte recruitment. 48 Secondly, disruption of protein heteromers formed by neutrophil and platelet secretory products efficiently reduces myeloid cell adhesion. Recently, peptides disturbing the interaction between CCL5 and defensin have been designed to lower monocyte recruitment into the heart thereby improving myocardial function. 49 Similarly, disruption of protein heteromers formed between platelet-borne CCL5 and CXCL4 prevents neutrophils recruitment in mouse models of acute lung injury. 17 Of note, both of the above strategies circumvent targeting CCL5 directly, which may possibly have serious side effects including impairment of polyclonal and antigenspecific T-cell proliferation, delayed viral clearance and aggravates glomerulonephritis. [50] [51] [52] The recent complete mapping of chemokine interactions may facilitate the design of additional specific therapeutic strategies. 53 Third, the use of endogenous inhibitors of leucocyte recruitment may serve to override chemokine-driven integrin activation. For example, annexin A1 and GDF15 (growth differentiation factor 15) can counteract conformation changes in neutrophil integrins which is in part mediated by platelet chemokines. Intracellularly, these endogenous inhibitors interfere with the activity of RAP1 GTPase and, consequently, suppress neutrophil recruitment during inflammation. 54, 55 Fourth, keeping neutrophils and platelets apart, endogenous inhibitors of leucocyte recruitment have not just been used to inhibit chemokine-driven firm adhesion to endothelium but also to prevent platelet-neutrophil aggregation. In this context, GDF15 blocks the activation of aIIbb3 integrins on platelets and hence limits the formation of platelet-neutrophil aggregates and subsequent neutrophil recruitment into the lungs. 56 In addition, with the striking importance of P-selectin and PSGL-1 in the platelet-neutrophil interplay, inhibition of PSGL-1 has been shown to be beneficial in acute lung injury, stroke and liver damage. 13 
| Inhibition of NET-driven inflammation
Given the importance of NET release as a consequence of neutrophil-platelet encounter, several strategies have emerged to target this process. Neutralization of the igniting stimulus is one feasible option. Herein, platelet-derived CCL5-CXCL4 heteromers stimulate NET formation and their disruption with peptide interference prevents NET discharge in a model of acute lung inflammation, improves subsequent lung function and mitigates lung damage. 15 Heteromer disruption in this way also inhibits recruitment of neutrophils to inflamed lungs. 17 In a similar fashion, inhibition of Mac1 blocks platelet-mediated NET release and consequently reduces lung damage. 15 In addition, signalling pathways activated during NET release are obvious targets. Phosphorylation of ERK in both platelets and neutrophils is necessary for the formation of NETs mediated by activated platelets. 29, 30 Consequently, inhibition of ERK phosphorylation limits NET release. In addition, Src and PI3K activation are triggered during NET formation mediated by platelets, 30, 57 and hence, these signalling pathways may be suitable targets to inhibit NET release. One critical step during NET formation is chromatin decondensation, which is associated with histone citrullination, a process catalysed by PAD4. Treatment with Cl-amidine, a specific PAD4 inhibitor, or its novel derivatives reduce NET release and disease severity in various mouse models of chronic inflammation including early stages of atherosclerosis which are typically orchestrated by platelets and neutrophils. 58, 59 In the context of myocardial infarction, it has recently been shown that NET burden is a predictor of infarct size as well as infract resolution. 60 Mechanistically, interaction of thrombin-activated platelets with neutrophils triggers local NET release and delivery and presentation of tissue factor consequently promoting coagulation. 61 Further work revealed that the signal delivered by platelets to stimulate NET release is inorganic polyphosphate (polyP). PolyP promoted mTOR inhibition with consequent autophagy induction. Therapeutically, IL29 was shown to inhibit autophagy-induced NET formation via mTOR phosphorylation and hence to limit arterial thrombosis. 62 in a similar fashion therapeutics targeting neutrophil autophagy such as chloroquine may help to limit NET release. Finally, cytotoxic components within NETs may be targeted to hinder inflammation. NETs are rich in cationic proteins, some of which exert macrophage activating and cytotoxic activities. Charge interactions can be employed to neutralize these proteins. As an example, a nonanticoagulant form of heparin was generated to bind NET-histones and found to prevent histone-induced cell death in a mouse model of sepsis. 63 The strategies outlined here can only exemplify some approaches tested in preclinical models.
For a comprehensive overview, the reader is directed to recent reviews. 64 
| CONCLUSION
Platelets have traditionally been recognized for their irreplaceable role in haemostasis, but their participation in innate immune responses may be equally important. At this point, a growing body of evidence points towards the importance of platelets during neutrophil trafficking and the release of NETs as well as diseases associated herewith such as lung injury and atherosclerosis. To derive specific means of interference from such information, it is required to better define the environmental cues responsible for a certain response triggered in platelets and neutrophils. That way organ-specific therapeutic approaches with limited systemic side effects could be designed.
